Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ract in a process that ultimately results in the persistent inflammation underlying IBD. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the GI system.

"Current approaches to the treatment of Crohn's disease often result in serious side effects, especially following long-term use of these drugs," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "These results suggest that Traficet-EN has the potential to keep Crohn's patients in remission without complications such as broad immunosuppression associated with current therapies."

"Data generated from these two studies are groundbreaking in nature and have the potential to revolutionize the way Crohn's disease and ulcerative colitis are treated," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are particularly pleased that we have for the first time definitively identified the CCR9 chemokine ligand in the large bowel which will broaden the scope of digestive tract disorders that Traficet-EN could potentially treat successfully."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

The randomized, placebo-controlled, double-blind clinical trial of 436 patients is comprised of three discrete periods which allows for evaluation of efficacy and safety of Traficet-EN in inducing a cl
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 ... Global Azithromycin Industry and 2015 Deep Research ... added to Pharmaceutical category in its database.  ... introduces Azithromycin basic information, including definition, classification, ... analysis, and news analysis, etc. Azithromycin Key ...
(Date:4/1/2015)...  Egalet Corporation (Nasdaq: EGLT ) ("Egalet"), ... developing, manufacturing and marketing innovative pain treatments, today ... million aggregate principal amount of its convertible senior ... placement to qualified institutional buyers pursuant to Rule ... amended (the "Act"). Egalet also granted the initial ...
(Date:4/1/2015)... SAN CLEMENTE, Calif. , April 1, 2015 /PRNewswire/ ... residents in the United States ... out amongst their resident colleagues. In its inaugural year, ... and 50 of the top nominations were narrowed to ... voting process that saw over 10,000 votes from colleagues ...
Breaking Medicine Technology:Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 2Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 3Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 4
... , , , , ... i c , Inc. (Nasdaq: ... medical imaging systems and surgical products dedicated to serving the healthcare needs ... study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic ...
... VIENNA, Va., Aug. 18 CEL-SCI Corporation (NYSE Amex: ... of its work towards creating a novel treatment and vaccination against ... in which the virus has acquired greater morbidity and mortality. ... are highly conserved and essential for the virus, survival. This ...
Cached Medicine Technology:Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 2Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 3Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 4CEL-SCI Expands H1N1 Flu Virus Work 2CEL-SCI Expands H1N1 Flu Virus Work 3
(Date:4/1/2015)... SCI Solutions , the health industry’s ... that CEO Joel French will be a featured speaker ... in Chicago, April 12-16, 2015. French will co-present ... Coordination Strategies ” with Northeast Georgia Health System (NGHS) ... than 38,000 healthcare industry professionals are expected at the ...
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... IQ Formulations , one of the most highly regarded ... U.S., today is commending GNC for taking steps to boost ... herbal supplements.* GNC vowed that its new processes will look ... labeling on its products. , In response to this ... Jay Cohen said: , “In a lightly-regulated industry where ...
(Date:4/1/2015)... April 01, 2015 Boys & Girls ... national leader in water safety education, today announced at ... and the Georgia Children’s Cabinet, that the organizations will ... water safety skills and swim instruction to thousands of ... Camp. The partnership provides swimming-safety instruction to more ...
(Date:4/1/2015)... On May 1, 2015, the Excelsior College ... Institute in Albany, New York . This year’s event will ... feature an address by Helen R. Connors, PhD, RN, Dr ... Kansas School of Nursing and Center for Healthcare Informatics. , ... the Excelsior College School of Nursing, Kinsinger Institute for ...
Breaking Medicine News(10 mins):Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 2Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 3Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 4Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 3
... arterial oxygenation deficiency occurs due to intra-pulmonary vascular ... disease. HPS occurs in 15-20% of patients with ... Recent studies support that the presence of HPS ... with decompensated liver disease. , One of ...
... parents would hotly deny favouring one child over another but ... matter. , Biologists studying a unique species of beetle that ... instinctively favour the oldest offspring. , The University of Manchester ... findings of studies carried out on human families but is ...
... New Year Favorite, and ,Have Fun Helping It ... ... terror attack?,Pandemic? Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude ... made its debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: ...
... Dec. 19 K2 Sports announced today the January,2008 ... care products developed,and tested to satisfy the extraordinary demands ... altitudes. Answering the call from,medical professionals concerned with the ... will feature three high performance,products: the K2 Endurance Sunblock ...
... as a lender under the line of ... credit., ... negotiated an increase in its secured revolving,line of credit with LaSalle Bank National ... the line of credit has increased from $50 million to $80,million. The line ...
... Dec. 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... British,Columbia Supreme Court has issued a final order ... (SWX: GALN), through a wholly-owned,Canadian subsidiary, will acquire ... US$26.00 per share in cash., The transaction, ...
Cached Medicine News:Health News:Who is the arch-criminal in the development of hepatopulmonary syndrome? 2Health News:Parents show bias in sibling rivalry, says study 2Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:K2 Sports Announces New Endurance Suncare Product Rollout for 2008 2Health News:K2 Sports Announces New Endurance Suncare Product Rollout for 2008 3Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 2Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 3Health News:Aspreva receives final court approval for acquisition by Galenica 2Health News:Aspreva receives final court approval for acquisition by Galenica 3Health News:Aspreva receives final court approval for acquisition by Galenica 4
Stryker bariatric laparoscopes set the standard in picture quality....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
The Concept Plus also allows users to transfer large bottles, flasks and other equipment, quickly and efficiently. The front-loading interlock features class leading one touch operation and easy acce...
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Medicine Products: